Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates
- 7 July 2026
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Abstract
Background: Antibody–drug conjugates have substantially improved outcomes for patients with HER2-positive (HER2+) metastatic breast cancer. Whether these survival gains have translated equitably across racial and ethnic groups remains unclear despite persistent disparities in breast cancer outcomes. Methods: We conducted a retrospective cohort study using de-identified electronic health record data from the TriNetX Research Network (2010-2024). Adults with HER2+ metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) were included. Overall survival was estimated using Kaplan–Meier methods and compared across racial and ethnic groups. Multivariable Cox models adjusted for age, body mass index, chronic obstructive pulmonary disease, hypertension, diabetes mellitus, and prior lines of therapy. Results: The cohort included 7462 patients with HER2+ metastatic breast cancer: 5072 non-Hispanic White (68%), 1193 Black (16%), 746 Hispanic (10%), and 298 Asian (4%). Five-year overall survival was highest among Asian (89.9%) and Hispanic (86.3%) patients, followed by non-Hispanic White (84.0%) and Black patients (80.3%) (P < .001). Compared with non-Hispanic White patients, Black patients experienced worse overall survival (adjusted hazard ratio [HR] = 1.22, 95% confidence interval [CI] = 1.03 to 1.45; P = .03). Survival differences among Asian and Hispanic patients were not observed after multivariable adjustment. Conclusions: Among patients with HER2+ metastatic breast cancer treated with HER2-directed antibody–drug conjugates, Black patients experienced persistently inferior survival despite receipt of effective therapies. These findings highlight ongoing inequities and underscore the need for interventions to ensure equitable translation of therapeutic advances across all populations.Keywords
This publication has 48 references indexed in Scilit:
- Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020JAMA Network Open, 2025
- Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Network Open, 2023
- Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast CancerJAMA Network Open, 2023
- Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast CancerJAMA Network Open, 2023
- Health and Racial Disparity in Breast Cancer2019
- Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancerCancer, 2018
- Immigration factors and prostate cancer survival among Hispanic men in California: Does neighborhood matter?Cancer, 2014
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Research and Treatment, 2010
- Racial and ethnic differences in breast cancer survivalCancer, 2007
- Participation in Cancer Clinical TrialsJAMA, 2004